Page 46 - Read Online

Page 14 of 14 Bittoni et al. J Cancer Metastasis Treat 2018;4:55 I http://dx.doi.org/10.20517/2394-4722.2018.37

doi: 10.1200/JCO.2016.34.15_suppl.3539.
51. Shahda S, Noonan AM, Bekaii-Saab TS, O’Neil BH, Sehdev A, et al. A phase II study of pembrolizumab in combination with mFOLFOX6
for patients with advanced colorectal cancer. J Clin Oncol 2017; doi: 10.1200/JCO.2017.35.15_suppl.3541.
52. Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, et al. Entinostat neutralizes myeloid-derived suppressor cells and
enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res 2017;23:5187-201.
53. Azad NS, Shirai K, McRee AJ, Opyrchal M, Johnson DB, et al. ENCORE 601: a phase 2 study of entinostat in combination with
pembrolizumab in patients with microsatellite stable metastatic colorectal cancer. J Clin Oncol 2018; doi: 10.1200/JCO.2018.36.15_
suppl.3557.
54. Magee MS, Abraham TS, Baybutt TR, Flickinger JC Jr, Ridge NA, et al. Human GUCY2C-targeted chimeric antigen receptor (CAR)-
expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Res 2018;6:509-16.
55. Huang Q, Xia J, Wang L, Wang X, Ma X, et al. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. J Hematol
Oncol 2018;11:58.
56. Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, et al. Beyond microsatellite testing: assessment of tumor mutational burden
identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. J Gastrointest Oncol 2018;9:610-7.